

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/62, C07K 14/52, C12N 15/19, 1/19, 5/10, 15/58	A1	(11) International Publication Number: WO 96/17067 (43) International Publication Date: 6 June 1996 (06.06.96)
(21) International Application Number: PCT/US95/14932 (22) International Filing Date: 15 November 1995 (15.11.95) (30) Priority Data: 08/247,029 30 November 1994 (30.11.94) US (71) Applicant: ZYMOGENETICS, INC. [US/US]; 1201 Eastlake Avenue East, Seattle, WA 98102 (US). (72) Inventors: FOSTER, Donald, C.; 3002 N.E. 181st Street, Seattle, WA 98155 (US). HEIPEL, Mark, D.; 8021 Earl Avenue N.W., Seattle, WA 98117 (US). HOLLY, Richard, D.; 12539 10th Avenue N.W., Seattle, WA 98177 (US). (74) Agent: PARKER, Gary, E.; ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA 98102 (US).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHOD FOR SECRETING THROMBOPOIETIN POLYPEPTIDES (57) Abstract DNA constructs useful in the production of thrombopoietin are disclosed. In general, the DNA constructs comprise a first DNA segment encoding a fusion of an amino-terminal secretory peptide joined to a thrombopoietin polypeptide and one or more additional DNA segments that provide for the transcription of the first segment. The secretory peptide is a native mammalian t-PA secretory peptide or may be modified to enhance proteolytic cleavage of the fusion. Also disclosed are cultured eukaryotic cells containing these DNA constructs and methods for producing thrombopoietin polypeptides through the use of the DNA constructs and cultured eukaryotic cells.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Description

5 METHOD FOR SECRETING THROMBOPOIETIN POLYPEPTIDES

Background of the Invention

Hematopoiesis is the process by which blood cells develop and differentiate from pluripotent stem cells in the bone marrow. This process involves a complex interplay of polypeptide growth factors (cytokines) acting via membrane-bound receptors on the target cells. Cytokine action results in cellular proliferation and differentiation, with a response to a particular cytokine often being lineage-specific and/or stage-specific. Development of a single cell type, such as a platelet, from a stem cell may require the coordinated action of a plurality of cytokines acting in the proper sequence.

The known cytokines include the interleukins, such as IL-1, IL-2, IL-3, IL-6, IL-8, etc.; and the colony stimulating factors, such as G-CSF, M-CSF, GM-CSF, erythropoietin (EPO), etc. In general, the interleukins act as mediators of immune and inflammatory responses. The colony stimulating factors stimulate the proliferation of marrow-derived cells, activate mature leukocytes, and otherwise form an integral part of the host's response to inflammatory, infectious, and immunologic challenges.

Various cytokines have been developed as therapeutic agents. For example, erythropoietin, which stimulates the development of erythrocytes, is used in the treatment of anemia arising from renal failure. Several of the colony stimulating factors have been used in conjunction with cancer chemotherapy to speed the recovery of patients' immune systems. Interleukin-2, α -interferon and γ -interferon are used in the treatment of certain cancers. An activity that stimulates megakaryocytopoiesis and thrombocytopoiesis has been identified in body fluids

of thrombocytopenic animals and is referred to in the literature as "thrombopoietin" (recently reviewed by McDonald, Exp. Hematol. 16:201-205, 1988 and McDonald, Am. J. Ped. Hematol. Oncol. 14:8-21, 1992).

- 5 Recently, several groups have identified and/or cloned a protein that binds to the cellular mpl receptor and stimulates megakaryocytopoiesis and thrombocytopoiesis. See, de Sauvage et al., Nature 369:533-538, 1994; Lok et al., Nature 369:565-568, 1994; 10 Kaushansky et al., Nature 369:568-571, 1994; Wendling et al., Nature 369:571-574, 1994; and Bartley et al., Cell 77:1117-1124, 1994. It has been proposed that this protein be termed thrombopoietin (Kaushansky et al., *ibid.*).
- 15 Analysis of amino acid sequences indicates that the mature mouse TPO extends from amino acid residue 45 (Ser) to residue 379 (Thr) of SEQ ID NO: 2. The predicted amino terminus of the human protein corresponds precisely to the demonstrated mature amino terminus for recombinant 20 murine TPO (Lok et al., *ibid.*), i.e. it is at Ser (22) of SEQ ID NO:4, with the protein extending to amino acid residue 353 of SEQ ID NO:4. TPO is subject to proteolysis and has been isolated in heterogeneous or degraded form (de Sauvage et al., Nature 369:533-538, 1994; Bartley et 25 al., Cell 77:1117-1124, 1994). Molecular species as small as 25 kD have been found to be active *in vitro* (Bartley et al., *ibid.*), and recombinant human TPO polypeptides of 153 (de Sauvage et al., *ibid.*) and 174 amino acids (Bartley et al., *ibid.*) have been reported as being active *in vitro*, as 30 has the product of expression of the full-length human cDNA, which encodes a primary translation product of 353 amino acids (Bartley et al., *ibid.*).

Thrombopoietin appears to be subject to proteolysis and was isolated in heterogeneous or degraded 35 form (Bartley et al., *ibid.*; de Sauvage et al., *ibid.*). Preparations of thrombopoietin reported in the scientific

literature are therefore not well characterized as to composition and the relative activities of the various molecular species, although at least some of the proteolytic products are biologically active. However, little work has been done to date on the large-scale production of thrombopoietin, and there remains a need in the art for methods of producing the protein in large amounts and in a cost-effective manner.

10 Summary of the Invention

It is an object of the present invention to provide methods for the production of thrombopoietin.

It is a further object of the present invention to provide methods for directing the secretion of recombinant thrombopoietin from host cells.

It is yet a further object of the invention to provide DNA constructs that direct the expression and secretion of high levels of thrombopoietin.

Within one aspect of the present invention there is provided a DNA construct comprising (a) a first DNA segment encoding a polypeptide fusion, the fusion comprising an amino-terminal secretory peptide joined to a thrombopoietin (TPO) polypeptide, the joined peptide and polypeptide defining a proteolytic cleavage site at their junction; and (b) one or more additional DNA segments operably linked to the first DNA segment so as to provide for its transcription, wherein the secretory peptide is selected from the group consisting of native mammalian tissue plasminogen activator (t-PA) secretory peptides and mammalian t-PA secretory peptides modified to enhance proteolytic cleavage at the junction. Within one embodiment, the secretory peptide is a human t-PA secretory peptide. Within a related embodiment, the secretory peptide consists of a sequence of amino acid residues as shown in SEQ ID NO:5 wherein Xaa(29), Xaa(31) and Xaa(33) are individually any amino acid and Xaa(34) is

Ala, Arg or Lys. Within another embodiment, Xaa(29) and Xaa(31) are individually any amino acid except Lys, Arg or His. Within additional embodiments, Xaa(33) is Gly; Xaa(34) is Arg or Lys; Xaa(29) and Xaa(31) are individually Asp, Glu, Gln, Gly or Ala, Xaa(33) is Gly, and Xaa(34) is Arg; or Xaa(29) is Arg or Glu, Xaa(31) is Arg or Gln, Xaa(33) is Gly, and Xaa(34) is Arg, subject to the limitation that at least one of Xaa(29) and Xaa(31) is not Arg. Within another embodiment, the TPO polypeptide consists of from 144 to 335 amino acid residues. Within a related embodiment, the TPO polypeptide consists of from 144 to 191 amino acid residues. Within another embodiment, the TPO polypeptide consists of a sequence of amino acids selected from the group consisting of a sequence as shown in SEQ ID NO:4 from Ser(22) to Val(173), Ser(22) to Arg(185), Ser(22) to Asn(193), Ser(22) to Phe(207), or Ser(22) to Gln(235).

Within another aspect of the invention there is provided a DNA construct comprising a first DNA segment encoding a polypeptide fusion consisting essentially of an amino-terminal secretory peptide as shown in SEQ ID NO:5 wherein Xaa(29) is Arg or Glu, Xaa(31) is Arg or Gln, Xaa(33) is Gly, and Xaa(34) is Ala or Arg, joined to a TPO polypeptide of from 144 to 335 amino acids, wherein the first DNA segment is operably linked to one or more additional DNA segments that provide for its transcription. Within one embodiment, the TPO polypeptide consists of from 144 to 191 amino acid residues. Within another embodiment, the TPO polypeptide is a human TPO polypeptide. Within another embodiment, the TPO polypeptide consists of a sequence of amino acids selected from the group consisting of a sequence as shown in SEQ ID NO:4 from Ser(22) to Val(173), Ser(22) to Arg(185), Ser(22) to Asn(193), Ser(22) to Phe(207), or Ser(22) to Gln(235). Within another embodiment, the DNA construct further comprises a selectable marker.

Within a third aspect, the present invention provides a cultured eukaryotic cell containing a DNA construct as disclosed above. Within one group of embodiments, the cell is a yeast cell, such as a *Saccharomyces cerevisiae* cell or a *Pichia pastoris* cell. Within another group of embodiments, the cell is a mammalian cell, such as a rodent cell or a kidney cell.

Within a fourth aspect of the invention there is provided a method for producing a thrombopoietin polypeptide comprising the steps of culturing a eukaryotic cell as disclosed above wherein the cell expresses the first DNA segment and the TPO polypeptide is secreted from the cell, and the TPO polypeptide is selectively recovered.

These and other aspects of the invention will become evident upon reference to the following detailed description.

Detailed Description of the Invention

Prior to describing the present invention in detail, it may be helpful to define certain terms used herein:

Allelic variant: An alternative form of a gene that arises through mutation, or an altered polypeptide encoded by the mutated gene. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequence.

cDNA: Complementary DNA, prepared by reverse transcription of a messenger RNA template, or a clone or amplified copy of such a molecule. Complementary DNA can be single-stranded or double-stranded.

Expression vector: A DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcription. Such additional segments include promoter and terminator sequences. An expression

vector may also include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, etc. Expression vectors are generally derived from plasmid or viral DNA, or may
5 contain elements of both. The term "operably linked" indicates that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in the promoter and proceeds through the coding segment to the terminator.

10 Gene: A segment of chromosomal DNA that encodes a polypeptide chain. A gene includes one or more regions encoding amino acids, which in some cases are interspersed with non-coding "intervening sequences" ("introns"), together with flanking, non-coding regions which provide
15 for transcription of the coding sequence.

Signal Sequence: A DNA sequence encoding a secretory peptide. Signal sequences are also called leader sequences, prepro sequences and pre sequences. A secretory peptide is an amino acid sequence that acts to
20 direct the secretion of a mature polypeptide or protein from a cell. Secretory peptides are characterized by a core of hydrophobic amino acids and are typically (but not exclusively) found at the amino termini of newly synthesized proteins. Very often the secretory peptide is
25 cleaved from the mature protein during secretion in one or more cleavage events. Such secretory peptides contain processing sites that allow cleavage of the secretory peptides from the mature proteins as they pass through the secretory pathway. The term "amino-terminal secretory
30 peptide" is used herein to denote a secretory peptide that occurs at the amino terminus of a protein (including fusion proteins).

Promoter: The portion of a gene at which RNA polymerase binds and mRNA synthesis is initiated.

35 Thrombopoietin: Thrombopoietin (TPO) proteins are characterized by their ability to specifically bind to

MPL receptor from the same species and to stimulate platelet production *in vivo*. In normal test animals, TPO is able to increase platelet levels by 100% or more within 10 days after beginning daily administration. The term "thrombopoietin polypeptide" encompasses full-length thrombopoietin molecules and biologically active portions thereof, that is fragments of a thrombopoietin that exhibit the qualitative biological activities of the intact molecule (receptor binding and *in vivo* stimulation of platelet production).

Amino acids are represented herein by the standard three-letter codes, with variable amino acids represented by "Xaa". Amino acid positions are designated by numbers in parentheses following the three-letter amino acid designations. For example, Ser(22) indicates a serine residue at position 22 of an amino acid sequence, and Xaa(29) indicates a variable amino acid at position 29 of a sequence. When a sequence contains a plurality of variable amino acids, each is represented by Xaa, although each may be a different amino acid residue.

The present invention provides methods for producing recombinant TPO polypeptides that are secreted from host cells expressing them, as well as DNA constructs, cells, and other materials that are useful within these methods.

Representative mouse and human TPO DNA and amino acid sequences are shown in SEQ ID NOS: 1, 2, 3 and 4. Those skilled in the art will recognize that the disclosed sequences represent single alleles, and that allelic variation is expected to exist. Allelic variants of the disclosed sequences are within the scope of the present invention.

The mouse and human TPO sequences disclosed herein can be used to design strategies and tools to clone additional TPO-encoding polynucleotides. The present

invention thus provides methods for preparing TPO polypeptides from a variety of species. Mammalian TPO polypeptides are preferred, including human, mouse, rat, porcine, canine, ovine, bovine and equine TPO polypeptides. Of particular interest are primate TPO polypeptides, in particular human TPO polypeptides.

Thrombopoietin polypeptides that can be produced according to the present invention include full-length thrombopoietin molecules, as well as truncated, biologically active fragments of the mature protein. In general these TPO polypeptides include at least the core "EPO-like domain" (so named because of its homology to erythropoietin) of the N-terminal region of the molecule. This core EPO-like domain is bounded by cysteine residues at positions 51 and 195 of mouse TPO (SEQ ID NO:2); positions 28 and 172 of human TPO (SEQ ID NO:4); and their counterpart residues in TPOs of other species. It has now been found that TPO polypeptides, such as a mouse TPO polypeptide extending from amino acid residue 45 (Ser) to residue 216 (Asn) of SEQ ID NO:2, are active in promoting platelet production in experimental animals. Particularly preferred TPO polypeptides are shown below in Table 1.

Table 1

Mouse TPO (SEQ ID NO:2)

25	Cys (residue 51)--Cys (residue 195)
	Cys (51)--Val (196)
	Cys (51)--Pro (206)
	Cys (51)--Ser (207)
	Cys (51)--Asn (216)
30	Cys (51)--Arg (235)
	Cys (51)--Arg (244)
	Cys (51)--Arg (249)
	Cys (51)--Gln (259)
	Cys (51)--Arg (273)
35	Ser (45)--Cys (195)
	Ser (45)--Val (196)

Table 1. continued

	Ser (45)--Pro (206)
	Ser (45)--Ser (207)
	Ser (45)--Asn (216)
5	Ser (45)--Arg (235)
	Ser (45)--Arg (244)
	Ser (45)--Arg (249)
	Ser (45)--Gln (259)
10	Ser (45)--Arg (273)
	Human TPO (SEQ ID NO:4)
	Cys (28)--Cys (172)
	Cys (28)--Val (173)
	Cys (28)--Arg (175)
15	Cys (28)--Arg (185)
	Cys (28)--Asn (193)
	Cys (28)--Arg (198)
	Cys (28)--Phe (207)
	Cys (28)--Gln (235)
20	Cys (28)--Arg (266)
	Ser (22)--Cys (172)
	Ser (22)--Val (173)
	Ser (22)--Arg (175)
	Ser (22)--Arg (185)
25	Ser (22)--Asn (193)
	Ser (22)--Arg (198)
	Ser (22)--Phe (207)
	Ser (22)--Gln (235)
30	Ser (22)--Arg (266)

Those skilled in the art will recognize that molecules having termini between the preferred amino- and carboxyl-terminal residues disclosed in Table 1 can be produced and would be expected to be biologically active.

Thrombopoietin polypeptides may include one or more amino acid substitutions, deletions or additions,

either from natural mutation or human manipulation of DNA. These changes are preferably of a minor nature, such as conservative amino acid substitutions that do not significantly affect the folding or activity of the protein (see Table 2). See, in general Ford et al., Protein Expression and Purification 2: 95-107, 1991, which is incorporated herein by reference.

Table 2

Conservative amino acid substitutions

10	Basic:	arginine
		lysine
		histidine
	Acidic:	glutamic acid
15		aspartic acid
	Polar:	glutamine
		asparagine
	Hydrophobic:	leucine
		isoleucine
20		valine
	Aromatic:	phenylalanine
		tryptophan
		tyrosine
	Small:	glycine
25		alanine
		serine
		threonine
		methionine

30 Essential amino acids in TPO can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244, 1081-1085, 1989). In the latter technique, single alanine mutations are
35 introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological

activity (e.g. receptor binding, *in vitro* or *in vivo* proliferative activity) to identify amino acid residues that are critical to the activity of the molecule. Sites of ligand-receptor interaction can also be determined by
5 analysis of crystal structure as determined by such techniques as nuclear magnetic resonance, crystallography or photoaffinity labeling. See, for example, de Vos et al., Science 255:306-312, 1992; Smith et al., J. Mol. Biol. 224:899-904, 1992; Wlodaver et al., FEBS Lett.
10 309:59-64, 1992.

In general, cytokines are predicted to have a four-alpha helix structure, with the first and fourth helices being most important in ligand-receptor interactions and more highly conserved among members of
15 the family. Referring to the human TPO amino acid sequence shown in SEQ ID NO:4, alignment of cytokine sequences suggests that these helices are bounded by amino acid residues 29 and 53, 80 and 99, 108 and 130, and 144 and 168, respectively (boundaries are ± 4 residues).
20 Helix boundaries of the mouse (SEQ ID NO:2) and other non-human TPOs can be determined by alignment with the human sequence. Other important structural aspects of TPO include the cysteine residues at positions 51, 73, 129 and 195 of SEQ ID NO:2 (corresponding to positions 28, 50, 106
25 and 172 of SEQ ID NO:4).

TPO polypeptides produced according to the present invention are characterized as having 50%, preferably 60%, more preferably at least 80%, sequence identity to the corresponding portion of the sequence
30 shown in SEQ ID NO: 2, the sequence shown in SEQ ID NO:4, or their species homologs. Such polypeptides will more preferably be at least 90% identical, and most preferably 95% or more identical to SEQ ID NO: 2 or SEQ ID NO:4 or their species homologs. Percent sequence identity is
35 determined by conventional methods. See, for example, Altschul et al., Bull. Math. Bio. 48: 603-616, 1986 and

Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915-10919, 1992. Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "blosum 62" scoring matrix of Henikoff and Henikoff (ibid.) as shown in Table 3 (amino acids are indicated by the standard one-letter codes). The percent identity is then calculated as:

$$\frac{\text{Total number of identical matches}}{\text{[length of the longer sequence plus the number of gaps introduced into the longer sequence in order to align the two sequences]}} \times 100$$

Table 3

	A	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W	Y	V
A	4																			
R	-1	5																		
N	-2	0	6																	
D	-2	-2	1	6																
C	0	-3	-3	-3	9															
Q	-1	1	0	0	-3	5														
E	-1	0	0	2	-4	2	5													
G	0	-2	0	-1	-3	-2	-2	6												
H	-2	0	1	-1	-3	0	0	-2	8											
I	-1	-3	-3	-3	-1	-3	-3	-4	-3	4										
L	-1	-2	-3	-4	-1	-2	-3	-4	-3	2	4									
K	-1	2	0	-1	-3	1	1	-2	-1	-3	-2	5								
M	-1	-1	-2	-3	-1	0	-2	-3	-2	1	2	-1	5							
F	-2	-3	-3	-3	-2	-3	-3	-3	-1	0	0	-3	0	6						
P	-1	-2	-2	-1	-3	-1	-1	-2	-2	-3	-3	-1	-2	-4	7					
S	1	-1	1	0	-1	0	0	0	-1	-2	-2	0	-1	-2	-1	4				
T	0	-1	0	-1	-1	-1	-1	-2	-2	-1	-1	-1	-2	-1	1	5				
W	-3	-3	-4	-4	-2	-2	-3	-2	-2	-3	-2	-3	-1	1	-4	-3	-2	11		
Y	-2	-2	-2	-3	-2	-1	-2	-3	2	-1	-1	-2	-1	3	-3	-2	-2	2	7	
V	0	-3	-3	-3	-1	-2	-2	-3	-3	3	1	-2	1	-1	-2	-2	0	-3	-1	4

TPO polypeptides may further include one or more additional, non-TPO, amino acid residues up to a total of about 20-25 residues, typically as an amino- or carboxyl-terminal extension of a polypeptide. Extensions of this type include, for example, an amino-terminal methionine residue, small linker peptides, and peptide extensions that facilitate purification of the polypeptide, such as a polyhistidine tract, an antigenic epitope, or a binding domain. See, in general, Ford et al., Protein Expression and Purification 2:95-107, 1991, which is incorporated herein by reference.

As noted above, TPO appears to be sensitive to proteolysis, and proteolytic products of the full-length (as inferred from cDNA sequence) molecule have been shown to be active. However, attempts in the inventors' laboratory to produce mouse TPO met with only limited success due to inefficient secretion of the polypeptide. The inventors discovered that by substituting a synthesized secretory peptide derived from that of human tissue-type plasminogen activator (t-PA), shown in SEQ ID NO:5, for the native TPO signal peptide, production of recoverable TPO in cultured baby hamster kidney (BHK) cells was increased by a factor of five to ten.

Within the present invention, a t-PA secretory peptide or derivative thereof is used to direct the secretion of TPO. In general, a DNA segment encoding a secretory peptide-TPO polypeptide fusion is operably linked to one or more additional DNA segments that provide for its transcription. Such additional DNA segments include a transcription promoter. It is preferred to also link the DNA sequence encoding a secretory peptide-TPO fusion to a transcription terminator, although transcription will in many cases terminate fortuitously within vector sequences downstream of the fusion sequence. The vector will commonly contain one or more selectable markers and one or more origins of replication, although those skilled in the art will recognize that within

certain systems selectable markers may be provided on separate vectors, and replication of the exogenous DNA may be provided by integration into the host cell genome. Selection of promoters, terminators, selectable markers, vectors and other elements is a matter of routine design within the level of ordinary skill in the art. Many such elements are described in the literature and are available through commercial suppliers.

To direct a TPO polypeptide into the secretory pathway of the host cell, a DNA sequence encoding a secretory peptide is joined to a DNA sequence encoding a TPO polypeptide in the correct reading frame so that the joined sequences encode a fusion protein. The joined secretory peptide and TPO polypeptide define a proteolytic cleavage site at their junction. In general, the present invention makes use of a secretory peptide having the sequence Met-Asp-Ala-Met-Lys-Arg-Gly-Leu-Cys-Cys-Val-Leu-Leu-Cys-Gly-Ala-Val-Phe-Val-Ser-Pro-Ser-Gln-Glu-Ile-His-Ala-Xaa-Phe-Xaa-Arg-Xaa-Xaa-Arg (SEQ ID NO:5) wherein Xaa(29), Xaa(31) and Xaa(33) are individually any amino acid and Xaa(34) is Ala, Arg or Lys. While the wild-type secretory peptide of human t-PA (wherein Xaa(29) and Xaa(31) are Arg, Xaa(33) is Gly and Xaa(34) is Ala) may be employed, it contains a pair of arginine residues at positions -4 and -5 (residues 31 and 32 of SEQ ID NO:5), which provide a proteolytic processing site. Cleavage can occur at this site, resulting in the production of a TPO polypeptide having three additional N-terminal amino acids. It is therefore preferred within the present invention to modify the DNA sequence encoding the secretory peptide to eliminate this processing site and to enhance processing at the junction of the t-PA and TPO sequences. While not wishing to be bound by theory, it is believed that secretory peptide cleavage is dependent upon a prohormone converting enzyme, such as the yeast KEX2 gene product or the mammalian enzymes PC1, PC2 and furin. Enzymes of this type recognize cleavage sites

characterized by arginine residues in the -1 and -4 positions. Cleavage is facilitated by a basic amino acid residue (e.g. Lys or Arg) in the -2 position. Within the present invention cleavage between the secretory peptide and TPO polypeptide may therefore be enhanced by providing arginine residues at the -1 and -4 positions, and optionally by providing a basic amino acid residue at the -2 position. Additional enhancement of the desired cleavage is achieved by replacing arginine residues elsewhere in the secretory peptide with other, preferably non-basic, amino acid residues, in particular where such residues form an Arg-Xaa-Xaa-Arg motif. Within a preferred embodiment, Xaa(29) and Xaa(31) in SEQ ID NO:5 are individually any amino acid except Lys, Arg or His. More preferably, Xaa(29) and Xaa(31) are individually Asp, Glu, Gln, Gly or Ala. Within another preferred embodiment, Xaa(33) is Gly. Within another preferred embodiment, Xaa(34) is Arg or Lys. Particularly preferred substitutions include Glu at Xaa(29), Gln at Xaa(31), and Arg at Xaa(34). Signal sequences are mutagenized by conventional methods, such as the polymerase chain reaction disclosed by Mullis et al., U.S. Patent No. 4,683,195 and Mullis, U.S. Patent No. 4,683,202, which are incorporated herein by reference in their entirety.

Secretory peptides from non-human t-PAs, and derivatives of non-human t-PA secretory peptides, may also be used. The DNA sequences encoding t-PA secretory peptides from various species are known in the art and have been disclosed by, for example, Rickles et al., J. Biol. Chem. 263:1563-1560, 1988 and Feng et al., J. Biol. Chem. 265:2022-2027, 1990. Such DNA sequences can be cloned as cDNA or genomic molecules according to techniques that are standard in the art, or can be synthesized, preferably using automated equipment and the application of conventional synthetic protocols.

Suitable host cells for use within the present invention include any type of cell that can be engineered

to express heterologous DNA, can be grown in culture, and has a secretory pathway. Although prokaryotic cells, such as *E. coli* cells, are capable of secreting proteins at least into the periplasmic space, it is preferred within
5 the present invention to use cultured eukaryotic cells, such as fungal cells or, in particular, cultured mammalian cells.

Yeast cells, particularly cells of the genus *Saccharomyces*, are useful in producing recombinant TPO
10 polypeptides. Yeast cells have a long history of use in the production of products for human consumption and are relatively inexpensive to culture. Methods for transforming yeast cells with exogenous DNA and producing recombinant proteins therefrom are disclosed by, for
15 example, Kawasaki, U.S. Patent No. 4,599,311; Kawasaki et al., U.S. Patent No. 4,931,373; Brake, U.S. Patent No. 4,870,008; Welch et al., U.S. Patent No. 5,037,743; and Murray et al., U.S. Patent No. 4,845,075, which are incorporated herein by reference. Transformed cells are
20 selected by phenotype determined by a selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e.g. leucine). A preferred vector system for use in yeast is the POT1 vector system disclosed by Kawasaki et al. (U.S. Patent
25 No. 4,931,373), which allows transformed cells to be selected by growth in glucose-containing media. Suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (see, e.g., Kawasaki, U.S. Patent No. 4,599,311; Kingsman et al., U.S. Patent No.
30 4,615,974; and Bitter, U.S. Patent No. 4,977,092, which are incorporated herein by reference) and alcohol dehydrogenase genes. See also U.S. Patents Nos. 4,990,446; 5,063,154; 5,139,936 and 4,661,454, which are incorporated herein by reference. Transformation systems
35 for other yeasts, including *Hansenula polymorpha*, *Schizosaccharomyces pombe*, *Kluyveromyces lactis*, *Kluyveromyces fragilis*, *Ustilago maydis*, *Pichia pastoris*,

Pichia guilliermondii and *Candida maltosa* are known in the art. See, for example, Gleeson et al., J. Gen. Microbiol. 132:3459-3465, 1986; Cregg, U.S. Patent No. 4,882,279; and Stroman et al., U.S. Patent No. 4,879,231.

5 Other fungal cells are also suitable as host cells. For example, *Aspergillus* cells may be utilized according to the methods of McKnight et al., U.S. Patent No. 4,935,349, which is incorporated herein by reference. Methods for transforming *Acremonium chrysogenum* are
10 disclosed by Sumino et al., U.S. Patent No. 5,162,228, which is incorporated herein by reference. Methods for transforming *Neurospora* are disclosed by Lambowitz, U.S. Patent No. 4,486,533, which is incorporated herein by reference.

15 As noted above, cultured mammalian cells are preferred hosts within the present invention. Methods for introducing exogenous DNA into mammalian host cells include calcium phosphate-mediated transfection (Wigler et al., Cell 14:725, 1978; Corsaro and Pearson, Somatic Cell
20 Genetics 7:603, 1981; Graham and Van der Eb, Virology 52:456, 1973), electroporation (Neumann et al., EMBO J. 1:841-845, 1982), DEAE-dextran mediated transfection (Ausubel et al., eds., Current Protocols in Molecular Biology, John Wiley and Sons, Inc., NY, 1987), and
25 cationic lipid-mediated transfection (Hawley-Nelson et al., Focus 15:73-79, 1993), which are incorporated herein by reference. The production of recombinant proteins in cultured mammalian cells is disclosed, for example, by Levinson et al., U.S. Patent No. 4,713,339; Hagen et al.,
30 U.S. Patent No. 4,784,950; Palmiter et al., U.S. Patent No. 4,579,821; and Ringold, U.S. Patent No. 4,656,134, which are incorporated herein by reference. Preferred cultured mammalian cells include the COS-1 (ATCC No. CRL 1650), COS-7 (ATCC No. CRL 1651), BHK (ATCC No. CRL 1632),
35 BHK 570 (ATCC No. CRL 10314), 293 (ATCC No. CRL 1573; Graham et al., J. Gen. Virol. 36:59-72, 1977) and Chinese hamster ovary (e.g. CHO-K1; ATCC No. CCL 61) cell lines.

Additional suitable cell lines are known in the art and available from public depositories such as the American Type Culture Collection, Rockville, Maryland. In general, strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus. See, e.g., U.S. Patent No. 4,956,288. Other suitable promoters include those from metallothionein genes (U.S. Patents Nos. 4,579,821 and 4,601,978, which are incorporated herein by reference) and the adenovirus major late promoter.

Drug selection is generally used to select for cultured mammalian cells into which foreign DNA has been inserted. Such cells are commonly referred to as "transfectants". Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as "stable transfectants." A preferred selectable marker is a gene encoding resistance to the antibiotic neomycin. Selection is carried out in the presence of a neomycin-type drug, such as G-418 or the like. Selection systems may also be used to increase the expression level of the gene of interest, a process referred to as "amplification." Amplification is carried out by culturing transfectants in the presence of a low level of the selective agent and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes. A preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate. Other drug resistance genes (e.g. hygromycin resistance, multi-drug resistance, puromycin acetyltransferase) can also be used.

Other higher eukaryotic cells can also be used as hosts, including insect cells, plant cells and avian cells. Transformation of insect cells and production of foreign proteins therein is disclosed by Guarino et al., U.S. Patent No. 5,162,222; Bang et al., U.S. Patent No. 4,775,624; and WIPO publication WO 94/06463, which are

incorporated herein by reference. The use of *Agrobacterium rhizogenes* as a vector for expressing genes in plant cells has been reviewed by Sinkar et al., J. Biosci. (Bangalore) 11:47-58, 1987.

5 Transformed or transfected host cells are cultured according to conventional procedures in a culture medium containing nutrients and other components required for the growth of the chosen host cells. A variety of
10 suitable media, including defined media and complex media, are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals. Media may also contain such components as growth factors or serum, as required. The growth medium
15 will generally select for cells containing the exogenously added DNA by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker carried on the expression vector or co-transfected into the host cell.

TPO prepared according to the present invention
20 is selectively recovered using methods generally known in the art, such as affinity purification and separations based on size, charge, solubility and other properties of the protein. When the protein is produced in cultured mammalian cells, it is preferred to culture the cells in a
25 serum-free culture medium in order to limit the amount of contaminating protein. The medium is harvested and fractionated. Preferred methods of fractionation include affinity chromatography, such as on an immobilized MPL receptor protein or ligand-binding portion thereof or
30 through the use of an affinity tag (e.g. polyhistidine, substance P or other polypeptide or protein for which an antibody or other specific binding agent is available). A specific cleavage site may be provided between the protein of interest and the affinity tag. Other chromatographic
35 methods can also be employed, such as cation exchange chromatography, anion exchange chromatography, and hydrophobic interaction chromatography.

TPO prepared according to the present invention can be used therapeutically wherever it is desirable to increase proliferation of cells in the bone marrow, such as in the treatment of cytopenia, such as that induced by aplastic anemia, myelodysplastic syndromes, chemotherapy or congenital cytopenias. TPO is also useful for increasing platelet production, such as in the treatment of thrombocytopenia. Thrombocytopenia is associated with a diverse group of diseases and clinical situations that may act alone or in concert to produce the condition. Lowered platelet counts can result from, for example, defects in platelet production, abnormal platelet distribution, dilutional losses due to massive transfusions, or abnormal destruction of platelets. For example, chemotherapeutic drugs used in cancer therapy may suppress development of platelet progenitor cells in the bone marrow, and the resulting thrombocytopenia limits the chemotherapy and may necessitate transfusions. In addition, certain malignancies can impair platelet production and platelet distribution. Radiation therapy used to kill malignant cells also kills platelet progenitor cells. Thrombocytopenia may also arise from various platelet autoimmune disorders induced by drugs, neonatal alloimmunity or platelet transfusion alloimmunity. TPO can reduce or eliminate the need for transfusions, thereby reducing the incidence of platelet alloimmunity. Abnormal destruction of platelets can result from: (1) increased platelet consumption in vascular grafts or traumatized tissue; or (2) immune mechanisms associated with, for example, drug-induced thrombocytopenia, idiopathic thrombocytopenic purpura (ITP), autoimmune diseases, hematologic disorders such as leukemia and lymphoma or metastatic cancers involving bone marrow. Other indications for TPO include aplastic anemia and drug-induced marrow suppression resulting from, for example, chemotherapy or treatment of HIV infection with AZT.

Thrombocytopenia is manifested as increased bleeding, such as mucosal bleedings from the nasal-oral area or the gastrointestinal tract, as well as oozing from wounds, ulcers or injection sites.

5 For pharmaceutical use, TPO is formulated for parenteral, particularly intravenous or subcutaneous, delivery according to conventional methods. Intravenous administration will be by bolus injection or infusion over a typical period of one to several hours. In general,
10 pharmaceutical formulations will include TPO in combination with a pharmaceutically acceptable vehicle, such as saline, buffered saline, 5% dextrose in water or the like. Formulations may further include one or more excipients, preservatives, solubilizers, buffering agents,
15 albumin to prevent protein loss on vial surfaces, etc. In addition, TPO may be combined with other cytokines, particularly early-acting cytokines such as stem cell factor, IL-3, IL-6, IL-11 or GM-CSF. When utilizing such a combination therapy, the cytokines may be combined in a
20 single formulation or may be administered in separate formulations. Methods of formulation are well known in the art and are disclosed, for example, in Remington's Pharmaceutical Sciences, Gennaro, ed., Mack Publishing Co., Easton PA, 1990, which is incorporated herein by
25 reference. Therapeutic doses of TPO will generally be in the range of 0.1 to 100 $\mu\text{g/kg}$ of patient weight per day, preferably 0.5-50 $\mu\text{g/kg}$ per day, with the exact dose determined by the clinician according to accepted standards, taking into account the nature and severity of
30 the condition to be treated, patient traits, etc. In certain cases, such as when treating patients showing increased sensitivity or requiring prolonged treatment, doses in the range of 0.1-20 $\mu\text{g/kg}$ per day will be indicated. Determination of dose is within the level of
35 ordinary skill in the art. TPO will commonly be administered over a period of up to 28 days following chemotherapy or bone-marrow transplant or until a platelet

count of $>20,000/\text{mm}^3$, preferably $>50,000/\text{mm}^3$, is achieved. More commonly, TPO will be administered over one week or less, often over a period of one to three days. In general, a therapeutically effective amount of TPO is an amount sufficient to produce a clinically significant increase in the proliferation and/or differentiation of lymphoid or myeloid progenitor cells, which will be manifested as an increase in circulating levels of mature cells (e.g. platelets or neutrophils). Treatment of platelet disorders will thus be continued until a platelet count of at least $20,000/\text{mm}^3$, preferably $50,000/\text{mm}^3$, is reached. TPO can also be administered in combination with other cytokines such as IL-3, -6 and -11; stem cell factor; erythropoietin; G-CSF and GM-CSF. Within regimens of combination therapy, daily doses of other cytokines will in general be: EPO, $\leq 150 \text{ U/kg}$; GM-CSF, $5\text{--}15 \mu\text{g/kg}$; IL-3, $1\text{--}5 \mu\text{g/kg}$; and G-CSF, $1\text{--}25 \mu\text{g/kg}$. Combination therapy with EPO, for example, is indicated in anemic patients with low EPO levels.

TPO is also a valuable tool for the *in vitro* study of the differentiation and development of hematopoietic cells, such as for elucidating the mechanisms of cell differentiation and for determining the lineages of mature cells, and may also find utility as a proliferative agent in cell culture.

TPO can also be used *ex vivo*, such as in autologous marrow culture. Briefly, bone marrow is removed from a patient prior to chemotherapy and treated with TPO, optionally in combination with one or more other cytokines. The treated marrow is then returned to the patient after chemotherapy to speed the recovery of the marrow. In addition, TPO can also be used for the *ex vivo* expansion of marrow or peripheral blood progenitor (PBPC) cells. Prior to chemotherapy treatment, marrow can be stimulated with stem cell factor (SCF) or G-CSF to release early progenitor cells into peripheral circulation. These progenitors can be collected and concentrated from

peripheral blood and then treated in culture with TPO, optionally in combination with one or more other cytokines, including but not limited to SCF, G-CSF, IL-3, GM-CSF, IL-6 or IL-11, to differentiate and proliferate
5 into high-density megakaryocyte cultures, which can then be returned to the patient following high-dose chemotherapy.

The invention is further illustrated by the following non-limiting examples.

10

Examples

Example 1

A human t-PA signal sequence was modified by a polymerase chain reaction using oligonucleotide primers
15 ZC7367 (SEQ ID NO:6) and ZC7738 (SEQ ID NO:7) and plasmid Thr102 (disclosed in WIPO publication WO 93/13208) as template. Ten ng of template DNA was combined with 5 μ l of 2 mM dNTPs, 5 μ l 10x Taq buffer (Boehringer Mannheim, Indianapolis, IN), 0.2 μ l Taq DNA polymerase (Boehringer
20 Mannheim), 40 pmole of each primer, and H₂O to 50 μ l. The mixture was incubated for 15 cycles of 95°C, 1 minute; 50°C, 2 minutes; and 72°C, 1 minute; followed by a final 10 minute incubation at 72°C. DNA was extracted with phenol/CHCl₃, precipitated with isopropanol at -20°C
25 overnight, and resuspended in 30 μ l H₂O. Ten μ l of the DNA was digested with BglII and EcoRI. The digested DNA was electrophoresed on a 2.2% agarose gel. The region of the gel corresponding to 124 bp was cut out and placed in a 0.5 ml microcentrifuge tube with a hole in the bottom on a
30 mat of aquarium filter floss. The tube was placed in an empty 1.5 ml tube, and the assembly was centrifuged to extract the DNA from the gel. Two μ g of glycogen was added to the extracted liquid, salt concentration was adjusted to 0.2 M NaCl, and the DNA was precipitated by
35 overnight incubation with ethanol at -20°C. The modified sequence encoded a human t-PA secretory peptide in which

the Arg residue at -7 was replaced with Glu, and the Ala residue at -2 was replaced with Arg.

To introduce a BglII site into the 5' end of the mouse TPO DNA sequence, pZGmpl-1081 (deposited under the terms of the Budapest Treaty on February 14, 1994 with American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD as assigned accession number 69566) was mutagenized by PCR. Mutagenesis was carried out using oligonucleotide primers ZC7365 (SEQ ID NO:8) and ZC7645 (SEQ ID NO:9). PCR was run for 20 cycles using conditions described above. DNA was phenol/chloroform extracted and precipitated with isopropanol.

The precipitated DNA was resuspended in H₂O and digested with PstI and BglII. A 313 bp fragment was recovered by gel electrophoresis and centrifugation as described above.

To prepare an expression vector, plasmid Zem229R (deposited under the terms of the Budapest Treaty with American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD on September 28, 1993 as an *E. coli* HB101 transformant and assigned Accession Number 69447) was digested with EcoRI and treated with alkaline phosphatase. The linearized vector was ligated with the t-PA leader sequence (EcoRI-BglII), the 313 bp PstI-BglII TPO fragment, and a PstI-EcoRI fragment encoding amino acid residues 150 through 196 of SEQ ID NO:2. The ligated DNA was used to transform competent DH10b™ *E. coli* cells (GIBCO BRL, Gaithersburg, MD), which were plated on media containing ampicillin and incubated overnight.

BHK 570 cells (ATCC CRL 10314) were plated in a 24-well dish at a density of 50,000 cells and incubated for about 15 hours. Plasmid DNA (designated TPO100.229R) was prepared from the transformed *E. coli* cells using a Wizard™ prep (Promega Corp., Madison, WI). Forty percent of the DNA (20 µl) was transfected into the BHK 570 cells using a 3:1 liposome formulation of 2,3-dioleoyloxy-N-[2(sperminecarboxyamido)ethyl]-N,N-dimethyl-1-

propanaminiumtrifluoroacetate and dioleoly-phosphatidylethanolamine in water (Lipofectamine™ reagent, GIBCO-BRL). Transfectants were selected in 500 nM methotrexate (MTX) in Dulbecco's modified Eagle's medium (DME; obtained from BioWhittaker, Inc., Walkersville, MD, or Fred Hutchinson Cancer Research Center, Seattle, WA) containing 5% heat-inactivated fetal bovine serum (BioWhittaker), 1 mM sodium pyruvate (Irvine Scientific, Santa Ana, CA), 2 mM L-glutamine (JRH Biosciences, Lexena, KS) and 25 mM HEPES (JRH Biosciences). Average production of TPO from the pool was 69,000--92,000 units (as defined in Example 10) per ml per day. Pools of transfectants and individual clones were then amplified in 10 μ M MTX and cloned by dilution. The amplified pool was found to produce 56,000 U/ml/day TPO.

Example 2

A vector for expression and secretion of full-length mouse TPO was constructed. TPO100.229R was digested with EcoRI and PstI, and the 437 bp fragment was isolated by gel electrophoresis and centrifugation as described above. A PstI-EcoRI fragment encoding amino acids 150-379 of SEQ ID NO:2 was prepared, and the two fragments were ligated with Zem229R that had been digested with EcoRI and treated with alkaline phosphatase. The ligation mixture was used to transform competent *E. coli* DH10b cells, which were then plated onto media containing ampicillin and incubated overnight.

Plasmid DNA (designated TPO101.229R) was prepared from the transformed *E. coli* cells and transfected into BHK 570 cells as described above. A pool of transfectants selected in 500 nM MTX produced 30,000 U/ml/day TPO. A pool of transfectants amplified with 10 μ M MTX produced 88,000 U/ml.

Example 3

A full-length mouse TPO DNA sequence was mutagenized by PCR to replace the arginine residues at positions 197-198 of SEQ ID NO:2 with glutamine residues.

5 The mutagenized TPO DNA (EcoRI-NotI) was ligated to EcoRI-digested Zem229R with a NotI/EcoRI oligonucleotide linker. The resulting plasmid was designated TPOM3.

Plasmid TPO100.229R was digested with EcoRI and SalI, and a 218 bp fragment encoding the t-PA leader and amino acid residues 45-76 of SEQ ID NO:2 was isolated. A 1188 bp fragment encoding amino acid residues 77-379 of SEQ ID NO:2 and including 3' untranslated DNA was prepared by digesting TPOM3 with SalI and EcoRI. These two fragments were ligated with Zem229R that had been digested with EcoRI and treated with alkaline phosphatase. The ligation mixture was used to transform competent *E. coli* DH10b™ cells, which were then plated onto media containing ampicillin and incubated overnight. The resulting plasmid was designated TPO110.229R.

20

Example 4

For expression of human TPO, a BglII site was introduced into the DNA sequence at the position of the codon for amino acid residue 22 (Ser) of SEQ ID NO:4. A polymerase chain reaction was carried out using a human TPO cDNA as template and oligonucleotide primers ZC7907 (SEQ ID NO:10) and 7693 (SEQ ID NO:11). Ten ng of template DNA was combined with 5 µl of 2 mM dNTPs, 5 µl 10x Taq buffer (Boehringer Mannheim), 0.2 µl Taq DNA polymerase (Boehringer Mannheim), 40 pmole of each primer, and H₂O to 50 µl. The mixture was incubated for 30 cycles of 95°C, 1 minute; 50°C, 2 minutes; and 72°C, 1 minute, with a final ten minute incubation at 72°C.

35 The PCR mixture was extracted with phenol/CHCl₃, and the DNA was precipitated with isopropanol and resuspended in H₂O. The resuspended DNA was digested with BglII and PstI, and a 316 bp fragment was recovered as

described above. This fragment encoded amino acid residues 22-126 of SEQ ID NO:4.

5 A t-PA leader sequence was prepared from TPO100.229R by digesting the plasmid with EcoRI and BglII and isolating the desired fragment (124 bp) by gel electrophoresis and centrifugation.

10 To construct a human TPO expression vector, a 710 bp PstI-EcoRI fragment encoding amino acid residues 127-353 of SEQ ID NO:4 was isolated and ligated with the PCR-generated fragment, the leader sequence, and Zem229R that had been digested with EcoRI and treated with alkaline phosphatase. The ligated DNA was used to transform competent *E. coli* DH10b™ cells. The plasmid was designated TPO201.229R.

15 The TPO201 sequence was placed in an expression vector under the control of an adenovirus major late promoter. Plasmid TPO201.229R was digested with EcoRI, and a 1149 bp fragment encoding the t-PA leader and TPO polypeptide was isolated. This DNA fragment was ligated
20 to the vector pDX (disclosed in U.S. Patent No. 4,959,318) which had been linearized by digestion with EcoRI and treated with alkaline phosphatase to construct plasmid TPO201.pDX.

BHK 570 cells cotransfected with TPO201.pDX and
25 Zem229R and selected in 5 μ M methotrexate produced up to 10,000-15,000 units TPO/ml/day.

Example 5

30 A vector was constructed for expression of a TPO polypeptide ending at amino acid residue 235 of SEQ ID NO:4. The human TPO DNA sequence was mutagenized by PCR to introduce two stop codons and an EcoRI site following the codon for amino acid 235. Ten ng of template DNA was combined with 5 μ l of 2 mM dNTPs, 5 μ l 10x Taq buffer
35 (Boehringer Mannheim), 0.2 μ l Taq DNA polymerase (Boehringer Mannheim), 40 pmole of each primer ZC7910 (SEQ ID NO:12) and ZC7878 (SEQ ID NO:13), and H₂O to 50 μ l.

The mixture was incubated for 30 cycles of 95°C, 1 minute; 50°C, 2 minutes; and 72°C, 1 minute, with a final ten minute incubation at 72°C. DNA was isolated from the reaction mixture and digested with PstI and Eco RI, and a
5 334 bp fragment encoding amino acid residues 127-235 of SEQ ID NO:4 was recovered as described above. This fragment was cloned into pIC19H and sequenced to confirm its identity.

The expression vector was then prepared. A 440
10 bp fragment encoding the t-PA leader and amino acid residues 22-126 of SEQ ID NO:4 was isolated from a EcoRI+PstI digest of TPO201.229R. The PCR-generated fragment was isolated from a EcoRI+PstI digest of the pIC19H clone. The two fragments were ligated with Zem229R
15 that had been digested with EcoRI and treated with alkaline phosphatase. The ligated DNA was used to transform competent *E. coli* DH10b™ cells. The plasmid was designated TPO200.229R.

Plasmid TPO200.229R was transfected into BHK 570
20 cells using Lipfectamine™ essentially as described in Example 1. The cells were plated in 24-well dish at a density of 40,000 cells/well one day prior to transfection. After initial selection in 500 nM MTX, pooled cells produced 1290 U/ml/day TPO. Following
25 amplification in 5 µM MTX, pooled cells produced 2330 U/ml/day TPO. A pool of cells amplified in 50 µM MTX produced 4700 U/ml/day.

A second expression vector was constructed comprising an adenovirus major late promoter, t-PA leader
30 and human TPO 22-235 sequence. Plasmid TPO200.229R was digested with EcoRI, and a 775 bp fragment encoding the t-PA leader and human TPO polypeptide was recovered. This DNA fragment was ligated to the vector pDX which had been linearized by digestion with EcoRI and treated with
35 alkaline phosphatase. The ligated DNA was transformed into *E. coli* MC1061 cells. The plasmid was designated TPO200.pDX.

TPO200.pDX was cotransfected into BHK 570 cells with Zem229R. Cells selected in 500 nM methotrexate produced up to 10,000-15,000 units TPO/ml/day.

5 Example 6

A vector was constructed for expression of a TPO polypeptide ending at amino acid residue 193 of SEQ ID NO:4. The human TPO DNA sequence was mutagenized by PCR to introduce a stop codon and an EcoRI site following the
10 codon for amino acid 193. Ten ng of template DNA was combined with 5 μ l of 2 mM dNTPs, 5 μ l 10x Taq buffer (Boehringer Mannheim), 0.2 μ l Taq DNA polymerase (Boehringer Mannheim), 40 pmole of each primer ZC8045 (SEQ ID NO:14) and ZC7878 (SEQ ID NO:13), and H₂O to 50 μ l.
15 The mixture was incubated for 30 cycles of 95°C, 1 minute; 50°C, 2 minutes; and 72°C, 1 minute, with a final ten minute incubation at 72°C. DNA was isolated from the reaction mixture and digested with PstI and Eco RI, and a 204 bp fragment encoding amino acid residues 127-193 of
20 SEQ ID NO:4 was recovered as described above.

To construct the expression vector, the isolated PCR product was ligated with the EcoRI-PstI fragment encoding the t-PA leader and amino acid residues 22-126 of SEQ ID NO:4 (Example 5) and Zem229R that had been digested
25 with EcoRI and treated with alkaline phosphatase. The ligated DNA was used to transform competent *E. coli* DH10b™ cells. The plasmid was designated TPO202.229R.

BHK 570 cells were transfected with TPO202.229R as described above and selected in 500 nM MTX. Pooled
30 cells produced 13,110 U/ml TPO. After amplification in 5 μ M MTX, pooled cells produced 20,850 U/ml/day TPO.

The 646 bp EcoRI insert was removed from TPO202.229R and ligated to pDX that had been linearized by digestion with EcoRI and treated with alkaline
35 phosphatase. The resulting vector, designated TPO202.pDX, was cotransfected into BHK 570 cells with Zem229R, or with AAT.229R. Cells cotransfected with TPO202.pDX and

AAT.229R and amplified with 500 nM MTX produced 20,500 U/ml/day TPO. TPO202.pDX/Zem229R cotransfectants amplified in 500 nM MTX produced 17,000 U/ml/day TPO.

5 Example 7

The Arg residue at position -5 in the t-PA leader was replaced with a Gln residue. A polymerase chain reaction was carried out using TPO100.229R as template, oligonucleotide primers ZC7367 (SEQ ID NO:6) and
10 ZC7956 (SEQ ID NO:15) and reaction conditions specified in Example 6. DNA was isolated as previously described and digested with EcoRI and BglII, and a 124 bp fragment encoding the modified t-PA leader was recovered.

To construct an expression vector, the 124 bp
15 PCR product was ligated with a BglII-EcoRI TPO-encoding fragment from TPO201.229R and Zem229R that had been digested with EcoRI and treated with alkaline phosphatase. The ligated DNA was used to transform competent *E. coli* DH10b™ cells. The plasmid was designated TPO251.229R.

20 BHK 570 cells were plated on a 24-well plate at 40,000 cells/well one day prior to transfection. After transfection with TPO251.229R and selection in MTX, pooled cells produced 1340 U/ml TPO. Following amplification in 5 μ M MTX, pooled cells produced 3940 U/ml TPO.

25

Example 8

A vector was constructed for the expression of a human TPO polypeptide ending at residue 235 of SEQ ID NO:4 with the modified t-PA leader of Example 7. Each of
30 TPO251.229R and TPO200.229R was digested with PstI and EcoRI. Fragments of 441 bp and 335 bp, respectively, were recovered. The two fragments were ligated with Zem229R that had been digested with EcoRI and treated with alkaline phosphatase. The ligated DNA was used to
35 transform competent *E. coli* MC1061 cells. The plasmid was designated TPO250.229R.

Plasmid TPO250.229R was transfected into BHK 570 cells. Pooled cells selected in 500 nM MTX produced 870 U/ml/day TPO. A pool of cells amplified in 50 μ M MTX produced 11,600 U/ml/day.

5 The 775 bp EcoRI insert was removed from TPO250.229R and ligated with pDX that had been linearized with EcoRI and treated with alkaline phosphatase. The resulting vector was designated TPO250.pDX. BHK 570 cells were cotransfected with TPO250.pDX and Zem229R. A pool of
10 cells amplified in 5 μ M MTX produced 21,900 U/ml/day TPO.

Example 9

A vector was constructed for the expression of a human TPO polypeptide ending at residue 193 of SEQ ID NO:4
15 with the modified t-PA leader of Example 7. Each of TPO250.229R and TPO202.229R was digested with PstI and EcoRI. Fragments of 441 bp and 205 bp, respectively, were recovered. The two fragments were ligated with Zem229R that had been digested with EcoRI and treated with
20 alkaline phosphatase. The ligated DNA was used to transform competent *E. coli* MC1061 cells. The plasmid was designated TPO252.229R.

TPO252.229R was transfected in BHK 570 cells. After selection in 500 nM MTX, pooled cells produced 8500
25 U/ml TPO. Following amplification in 5 μ M MTX, pooled cells produced 31,300 U/ml/day.

The TPO252 sequence was isolated from plasmid TPO252.229R and ligated with EcoRI-digested, alkaline phosphatase-treated pDX to construct TPO252.pDX. Cells
30 were cotransfected with TPO252.pDX and Zem229R. After amplification in 500 nM MTX, individual clones produced up to about 30,000 U/ml/day TPO.

Example 10

35 Units of TPO activity were determined by assaying mitogenic activity on a TPO-dependent cell line. A BHK 570 cell line transfected with the mouse TPO

expression vector pZGmpl-1081 was grown in serum-free medium. Conditioned culture medium was collected, and an asymptotic mitogenic activity curve was generated using this standard solution. The target cells were

5 BaF3/MPLR1.1 cells (IL-3-dependent cells expressing a stably transfected Type I mouse MPL receptor; deposited September 28, 1994 under the terms of the Budapest Treaty with American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD and assigned accession number CRL

10 11723). The point of 1/2 maximal activity (average of 16 curves) was assigned the value of 50 U/ml. The original standard solution was calculated to contain 26,600 U/ml mouse TPO.

For test samples, a culture supernatant or

15 purified protein preparation was diluted in RPMI 1640 medium supplemented with 57 μ M 2-mercaptoethanol, 2 mM L-glutamine, 1 mM sodium pyruvate, PSN antibiotic mixture, 10 mM HEPES and 10% heat inactivated fetal bovine serum, generally using 8-24 dilutions. Briefly, 100 μ l of

20 diluted test sample or standard sample and 100 μ l BaF3 cells (final cell number added about 10,000 cells/well) were combined in wells of a 96 well plate. Internal standards included eight 2-fold dilutions of 100 U/ml mouse TPO for mouse TPO assays, or eight 2-fold dilutions

25 of 150 U/ml mouse TPO for human TPO assays. To each well was added 2 μ l 3 H-thymidine (1 μ Ci/ μ l; Amersham), and the plates were incubated overnight at 37°C.

The contents of each well of each plate were transferred to a filter/plate using a Packard apparatus.

30 The filters were washed 8 times with water, and the filters were dried and counted. Units of TPO activity in each sample well were determined by comparison to the standard curve.

35

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been

described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: ZymoGenetics, Inc.
1201 Eastlake Avenue East
Seattle
WA
USA
98102

(ii) TITLE OF INVENTION: METHOD FOR SECRETING THROMBOPOIETIN
POLYPEPTIDES

(iii) NUMBER OF SEQUENCES: 15

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: ZymoGenetics, Inc.
(B) STREET: 1201 Eastlake Avenue East
(C) CITY: Seattle
(D) STATE: WA
(E) COUNTRY: USA
(F) ZIP: 98102

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Parker, Gary E
(B) REGISTRATION NUMBER: 31-648
(C) REFERENCE/DOCKET NUMBER: 94-13PC

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 206-442-6673
(B) TELEFAX: 206-442-6678

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1486 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 105..1241

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CCTCGTGCCG GTCCTGAGGC CCTTCTCCAC CCGGACAGAG TCCTTGCCCC ACCTCTCTCC	60
CACCCGACTC TGCCGAAAGA AGCACAGAAG CTCAAGCCGC CTCC ATG GCC CCA GGA	116
Met Ala Pro Gly	
1	
AAG ATT CAG GGG AGA GGC CCC ATA CAG GGA GCC ACT TCA GTT AGA CAC	164
Lys Ile Gln Gly Arg Gly Pro Ile Gln Gly Ala Thr Ser Val Arg His	
5 10 15 20	
CTG GCC AGA ATG GAG CTG ACT GAT TTG CTC CTG GCG GCC ATG CTT CTT	212
Leu Ala Arg Met Glu Leu Thr Asp Leu Leu Leu Ala Ala Met Leu Leu	
25 30 35	
GCA GTG GCA AGA CTA ACT CTG TCC AGC CCC GTA GCT CCT GCC TGT GAC	260
Ala Val Ala Arg Leu Thr Leu Ser Ser Pro Val Ala Pro Ala Cys Asp	
40 45 50	
CCC AGA CTC CTA AAT AAA CTG CTG CGT GAC TCC CAC CTC CTT CAC AGC	308
Pro Arg Leu Leu Asn Lys Leu Leu Arg Asp Ser His Leu Leu His Ser	
55 60 65	
CGA CTG AGT CAG TGT CCC GAC GTC GAC CCT TTG TCT ATC CCT GTT CTG	356
Arg Leu Ser Gln Cys Pro Asp Val Asp Pro Leu Ser Ile Pro Val Leu	
70 75 80	

CTG CCT GCT GTG GAC TTT AGC CTG GGA GAA TGG AAA ACC CAG ACG GAA Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Thr Glu 85 90 95 100	404
CAG AGC AAG GCA CAG GAC ATT CTA GGG GCA GTG TCC CTT CTA CTG GAG Gln Ser Lys Ala Gln Asp Ile Leu Gly Ala Val Ser Leu Leu Leu Glu 105 110 115	452
GGA GTG ATG GCA GCA CGA GGA CAG TTG GAA CCC TCC TGC CTC TCA TCC Gly Val Met Ala Ala Arg Gly Gln Leu Glu Pro Ser Cys Leu Ser Ser 120 125 130	500
CTC CTG GGA CAG CTT TCT GGG CAG GTT CGC CTC CTC TTG GGG GCC CTG Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu 135 140 145	548
CAG GGC CTC CTA GGA ACC CAG CTT CCT CTA CAG GGC AGG ACC ACA GCT Gln Gly Leu Leu Gly Thr Gln Leu Pro Leu Gln Gly Arg Thr Thr Ala 150 155 160	596
CAC AAG GAC CCC AAT GCC CTC TTC TTG AGC TTG CAA CAA CTG CTT CGG His Lys Asp Pro Asn Ala Leu Phe Leu Ser Leu Gln Gln Leu Leu Arg 165 170 175 180	644
GGA AAG GTG CGC TTC CTG CTT CTG GTA GAA GGT CCC ACC CTC TGT GTC Gly Lys Val Arg Phe Leu Leu Leu Val Glu Gly Pro Thr Leu Cys Val 185 190 195	692
AGA CGG ACC CTG CCA ACC ACA GCT GTC CCA AGC AGT ACT TCT CAA CTC Arg Arg Thr Leu Pro Thr Thr Ala Val Pro Ser Ser Thr Ser Gln Leu 200 205 210	740
CTC ACA CTA AAC AAG TTC CCA AAC AGG ACT TCT GGA TTG TTG GAG ACG Leu Thr Leu Asn Lys Phe Pro Asn Arg Thr Ser Gly Leu Leu Glu Thr 215 220 225	788
AAC TTC AGT GTC ACA GCC AGA ACT GCT GGC CCT GGA CTT CTG AGC AGG Asn Phe Ser Val Thr Ala Arg Thr Ala Gly Pro Gly Leu Leu Ser Arg 230 235 240	836
CTT CAG GGA TTC AGA GTC AAG ATT ACT CCT GGT CAG CTA AAT CAA ACC Leu Gln Gly Phe Arg Val Lys Ile Thr Pro Gly Gln Leu Asn Gln Thr 245 250 255 260	884

TCC AGG TCC CCA GTC CAA ATC TCT GGA TAC CTG AAC AGG ACA CAC GGA Ser Arg Ser Pro Val Gln Ile Ser Gly Tyr Leu Asn Arg Thr His Gly 265 270 275	932
CCT GTG AAT GGA ACT CAT GGG CTC TTT GCT GGA ACC TCA CTT CAG ACC Pro Val Asn Gly Thr His Gly Leu Phe Ala Gly Thr Ser Leu Gln Thr 280 285 290	980
CTG GAA GCC TCA GAC ATC TCG CCC GGA GCT TTC AAC AAA GGC TCC CTG Leu Glu Ala Ser Asp Ile Ser Pro Gly Ala Phe Asn Lys Gly Ser Leu 295 300 305	1028
GCA TTC AAC CTC CAG GGT GGA CTT CCT CCT TCT CCA AGC CTT GCT CCT Ala Phe Asn Leu Gln Gly Gly Leu Pro Pro Ser Pro Ser Leu Ala Pro 310 315 320	1076
GAT GGA CAC ACA CCC TTC CCT CCT TCA CCT GCC TTG CCC ACC ACC CAT Asp Gly His Thr Pro Phe Pro Pro Ser Pro Ala Leu Pro Thr Thr His 325 330 335 340	1124
GGA TCT CCA CCC CAG CTC CAC CCC CTG TTT CCT GAC CCT TCC ACC ACC Gly Ser Pro Pro Gln Leu His Pro Leu Phe Pro Asp Pro Ser Thr Thr 345 350 355	1172
ATG CCT AAC TCT ACC GCC CCT CAT CCA GTC ACA ATG TAC CCT CAT CCC Met Pro Asn Ser Thr Ala Pro His Pro Val Thr Met Tyr Pro His Pro 360 365 370	1220
AGG AAT TTG TCT CAG GAA ACA TAGCGCGGGC ACTGGCCCAG TGAGCGTCTG Arg Asn Leu Ser Gln Glu Thr 375	1271
CAGCTTCTCT CGGGGACAAG CTTCCCCAGG AAGGCTGAGA GGCAGCTGCA TCTGCTCCAG	1331
ATGTTCTGCT TTCACCTAAA AGGCCCTGGG GAAGGGATAC ACAGCACTGG AGATTGTAAA	1391
ATTTTAGGAG CTATTTTTTT TTAACCTATC AGCAATATTC ATCAGAGCAG CTAGCGATCT	1451
TTGGTCTATT TTCGGTATAA ATTTGAAAAT CACTA	1486

(2) INFORMATION FOR SEQ ID NO:2:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 379 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ala Pro Gly Lys Ile Gln Gly Arg Gly Pro Ile Gln Gly Ala Thr
1 5 10 15

Ser Val Arg His Leu Ala Arg Met Glu Leu Thr Asp Leu Leu Leu Ala
20 25 30

Ala Met Leu Leu Ala Val Ala Arg Leu Thr Leu Ser Ser Pro Val Ala
35 40 45

Pro Ala Cys Asp Pro Arg Leu Leu Asn Lys Leu Leu Arg Asp Ser His
50 55 60

Leu Leu His Ser Arg Leu Ser Gln Cys Pro Asp Val Asp Pro Leu Ser
65 70 75 80

Ile Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys
85 90 95

Thr Gln Thr Glu Gln Ser Lys Ala Gln Asp Ile Leu Gly Ala Val Ser
100 105 110

Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gln Leu Glu Pro Ser
115 120 125

Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu
130 135 140

Leu Gly Ala Leu Gln Gly Leu Leu Gly Thr Gln Leu Pro Leu Gln Gly
145 150 155 160

Arg Thr Thr Ala His Lys Asp Pro Asn Ala Leu Phe Leu Ser Leu Gln
165 170 175

Gln Leu Leu Arg Gly Lys Val Arg Phe Leu Leu Leu Val Glu Gly Pro
180 185 190

Thr Leu Cys Val Arg Arg Thr Leu Pro Thr Thr Ala Val Pro Ser Ser
195 200 205

Thr Ser Gln Leu Leu Thr Leu Asn Lys Phe Pro Asn Arg Thr Ser Gly
 210 215 220
 Leu Leu Glu Thr Asn Phe Ser Val Thr Ala Arg Thr Ala Gly Pro Gly
 225 230 235 240
 Leu Leu Ser Arg Leu Gln Gly Phe Arg Val Lys Ile Thr Pro Gly Gln
 245 250 255
 Leu Asn Gln Thr Ser Arg Ser Pro Val Gln Ile Ser Gly Tyr Leu Asn
 260 265 270
 Arg Thr His Gly Pro Val Asn Gly Thr His Gly Leu Phe Ala Gly Thr
 275 280 285
 Ser Leu Gln Thr Leu Glu Ala Ser Asp Ile Ser Pro Gly Ala Phe Asn
 290 295 300
 Lys Gly Ser Leu Ala Phe Asn Leu Gln Gly Gly Leu Pro Pro Ser Pro
 305 310 315 320
 Ser Leu Ala Pro Asp Gly His Thr Pro Phe Pro Pro Ser Pro Ala Leu
 325 330 335
 Pro Thr Thr His Gly Ser Pro Pro Gln Leu His Pro Leu Phe Pro Asp
 340 345 350
 Pro Ser Thr Thr Met Pro Asn Ser Thr Ala Pro His Pro Val Thr Met
 355 360 365
 Tyr Pro His Pro Arg Asn Leu Ser Gln Glu Thr
 370 375

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1062 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1059

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATG GAG CTG ACT GAA TTG CTC CTC GTG GTC ATG CTT CTC CTA ACT GCA	48
Met Glu Leu Thr Glu Leu Leu Val Val Met Leu Leu Leu Thr Ala	
1 5 10 15	
AGG CTA ACG CTG TCC AGC CCG GCT CCT CCT GCT TGT GAC CTC CGA GTC	96
Arg Leu Thr Leu Ser Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val	
20 25 30	
CTC AGT AAA CTG CTT CGT GAC TCC CAT GTC CTT CAC AGC AGA CTG AGC	144
Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser	
35 40 45	
CAG TGC CCA GAG GTT CAC CCT TTG CCT ACA CCT GTC CTG CTG CCT GCT	192
Gln Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala	
50 55 60	
GTG GAC TTT AGC TTG GGA GAA TGG AAA ACC CAG ATG GAG GAG ACC AAG	240
Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys	
65 70 75 80	
GCA CAG GAC ATT CTG GGA GCA GTG ACC CTT CTG CTG GAG GGA GTG ATG	288
Ala Gln Asp Ile Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met	
85 90 95	
GCA GCA CGG GGA CAA CTG GGA CCC ACT TGC CTC TCA TCC CTC CTG GGG	336
Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly	
100 105 110	
CAG CTT TCT GGA CAG GTC CGT CTC CTC CTT GGG GCC CTG CAG AGC CTC	384
Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu	
115 120 125	
CTT GGA ACC CAG CTT CCT CCA CAG GGC AGG ACC ACA GCT CAC AAG GAT	432
Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala His Lys Asp	
130 135 140	

CCC AAT GCC ATC TTC CTG AGC TTC CAA CAC CTG CTC CGA GGA AAG GTG Pro Asn Ala Ile Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val 145 150 155 160	480
CGT TTC CTG ATG CTT GTA GGA GGG TCC ACC CTC TGC GTC AGG CGG GCC Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Arg Ala 165 170 175	528
CCA CCC ACC ACA GCT GTC CCC AGC AGA ACC TCT CTA GTC CTC ACA CTG Pro Pro Thr Thr Ala Val Pro Ser Arg Thr Ser Leu Val Leu Thr Leu 180 185 190	576
AAC GAG CTC CCA AAC AGG ACT TCT GGA TTG TTG GAG ACA AAC TTC ACT Asn Glu Leu Pro Asn Arg Thr Ser Gly Leu Leu Glu Thr Asn Phe Thr 195 200 205	624
GCC TCA GCC AGA ACT ACT GGC TCT GGG CTT CTG AAG TGG CAG CAG GGA Ala Ser Ala Arg Thr Thr Gly Ser Gly Leu Leu Lys Trp Gln Gln Gly 210 215 220	672
TTC AGA GCC AAG ATT CCT GGT CTG CTG AAC CAA ACC TCC AGG TCC CTG Phe Arg Ala Lys Ile Pro Gly Leu Leu Asn Gln Thr Ser Arg Ser Leu 225 230 235 240	720
GAC CAA ATC CCC GGA TAC CTG AAC AGG ATA CAC GAA CTC TTG AAT GGA Asp Gln Ile Pro Gly Tyr Leu Asn Arg Ile His Glu Leu Leu Asn Gly 245 250 255	768
ACT CGT GGA CTC TTT CCT GGA CCC TCA CGC AGG ACC CTA GGA GCC CCG Thr Arg Gly Leu Phe Pro Gly Pro Ser Arg Arg Thr Leu Gly Ala Pro 260 265 270	816
GAC ATT TCC TCA GGA ACA TCA GAC ACA GGC TCC CTG CCA CCC AAC CTC Asp Ile Ser Ser Gly Thr Ser Asp Thr Gly Ser Leu Pro Pro Asn Leu 275 280 285	864
CAG CCT GGA TAT TCT CCT TCC CCA ACC CAT CCT CCT ACT GGA CAG TAT Gln Pro Gly Tyr Ser Pro Ser Pro Thr His Pro Pro Thr Gly Gln Tyr 290 295 300	912
ACG CTC TTC CCT CTT CCA CCC ACC TTG CCC ACC CCT GTG GTC CAG CTC Thr Leu Phe Pro Leu Pro Pro Thr Leu Pro Thr Pro Val Val Gln Leu 305 310 315 320	960

CAC CCC CTG CTT CCT GAC CCT TCT GCT CCA ACG CCC ACC CCT ACC AGC	1008
His Pro Leu Leu Pro Asp Pro Ser Ala Pro Thr Pro Thr Pro Thr Ser	
325 330 335	
CCT CTT CTA AAC ACA TCC TAC ACC CAC TCC CAG AAT CTG TCT CAG GAA	1056
Pro Leu Leu Asn Thr Ser Tyr Thr His Ser Gln Asn Leu Ser Gln Glu	
340 345 350	
GGG TAA	1062
Gly	

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 353 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met	Glu	Leu	Thr	Glu	Leu	Leu	Leu	Val	Val	Met	Leu	Leu	Leu	Thr	Ala
1				5					10						15
Arg	Leu	Thr	Leu	Ser	Ser	Pro	Ala	Pro	Pro	Ala	Cys	Asp	Leu	Arg	Val
			20					25					30		
Leu	Ser	Lys	Leu	Leu	Arg	Asp	Ser	His	Val	Leu	His	Ser	Arg	Leu	Ser
		35					40					45			
Gln	Cys	Pro	Glu	Val	His	Pro	Leu	Pro	Thr	Pro	Val	Leu	Leu	Pro	Ala
	50					55					60				
Val	Asp	Phe	Ser	Leu	Gly	Glu	Trp	Lys	Thr	Gln	Met	Glu	Glu	Thr	Lys
65					70				75						80
Ala	Gln	Asp	Ile	Leu	Gly	Ala	Val	Thr	Leu	Leu	Leu	Glu	Gly	Val	Met
			85					90							95
Ala	Ala	Arg	Gly	Gln	Leu	Gly	Pro	Thr	Cys	Leu	Ser	Ser	Leu	Leu	Gly
			100				105								110

Gln Leu Ser Gly Gln Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu
 115 120 125

Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg Thr Thr Ala His Lys Asp
 130 135 140

Pro Asn Ala Ile Phe Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val
 145 150 155 160

Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Arg Ala
 165 170 175

Pro Pro Thr Thr Ala Val Pro Ser Arg Thr Ser Leu Val Leu Thr Leu
 180 185 190

Asn Glu Leu Pro Asn Arg Thr Ser Gly Leu Leu Glu Thr Asn Phe Thr
 195 200 205

Ala Ser Ala Arg Thr Thr Gly Ser Gly Leu Leu Lys Trp Gln Gln Gly
 210 215 220

Phe Arg Ala Lys Ile Pro Gly Leu Leu Asn Gln Thr Ser Arg Ser Leu
 225 230 235 240

Asp Gln Ile Pro Gly Tyr Leu Asn Arg Ile His Glu Leu Leu Asn Gly
 245 250 255

Thr Arg Gly Leu Phe Pro Gly Pro Ser Arg Arg Thr Leu Gly Ala Pro
 260 265 270

Asp Ile Ser Ser Gly Thr Ser Asp Thr Gly Ser Leu Pro Pro Asn Leu
 275 280 285

Gln Pro Gly Tyr Ser Pro Ser Pro Thr His Pro Pro Thr Gly Gln Tyr
 290 295 300

Thr Leu Phe Pro Leu Pro Pro Thr Leu Pro Thr Pro Val Val Gln Leu
 305 310 315 320

His Pro Leu Leu Pro Asp Pro Ser Ala Pro Thr Pro Thr Pro Thr Ser
 325 330 335

Pro Leu Leu Asn Thr Ser Tyr Thr His Ser Gln Asn Leu Ser Gln Glu
340 345 350

Gly

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 29
- (D) OTHER INFORMATION: /note= "This amino acid can be any amino acid."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 31
- (D) OTHER INFORMATION: /note= "This amino acid can be any amino acid."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 33
- (D) OTHER INFORMATION: /note= "This amino acid can be any amino acid."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 34
- (D) OTHER INFORMATION: /note= "This amino acid can be Ala, Arg or Lys."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
1 5 10 15

Ala Val Phe Val Ser Pro Ser Gln Glu Ile His Ala Xaa Phe Xaa Arg
20 25 30

Xaa Xaa Arg
35

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- (vii) IMMEDIATE SOURCE:
(B) CLONE: ZC7367

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CGTCACCGGG AATTCATCGA TATCTAGATA TTAAGA

36

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- (vii) IMMEDIATE SOURCE:
(B) CLONE: ZC7738

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GCCTTCAGAT CTGCGTCCTC TTCTGAACTC GGCATGATTA AGA

43

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: ZC7365

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GCAAGACTAA CTCTGAGATC TCCCGTAGCT CCTGCCATTA AGA

43

- (2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 37 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: ZC7645

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

TGTAGAGGAA GCTGGGTTCC TAGGAGGCC ATTAAGA

37

- (2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: ZC7907

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GCAAGGCTAA CGCTGAGATC TCCGGCTCCT CCTGCTATTA AGA

43

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

(B) CLONE: ZC7693

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GGATCCTTGT GAGCTGTGGT CATTAAGA

28

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 46 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

(B) CLONE: ZC7910

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GATTGGTCC AGGAATTCCT ACTATTGGTT CAGCAGACCA TTAAGA

46

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:
(B) CLONE: ZC7878

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CCGTCTCCTC CTTGGGGCCC ATTAAGA

27

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:
(B) CLONE: ZC8045

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

AGAAGTCCTG TTTGAATTCT AGTTCAGTGT GAGGACATTA AGA

43

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:
(B) CLONE: ZC7956

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GCCTTCAGAT CTGCGTCCTC TTTGGAACTC GGCATGATTA AGA

43

Claims

We claim:

1. A DNA construct comprising:
a first DNA segment encoding a polypeptide fusion, said fusion comprising an amino-terminal secretory peptide joined to a thrombopoietin (TPO) polypeptide, the joined peptide and polypeptide defining a proteolytic cleavage site at their junction; and
one or more additional DNA segments operably linked to said first DNA segment so as to provide for its transcription, wherein said secretory peptide is selected from the group consisting of:
native mammalian tissue plasminogen activator (t-PA) secretory peptides; and
mammalian t-PA secretory peptides modified to enhance proteolytic cleavage at said junction.
2. A DNA construct according to claim 1 wherein said secretory peptide is a human t-PA secretory peptide.
3. A DNA construct according to claim 1 wherein said secretory peptide consists of a sequence of amino acid residues as shown in SEQ ID NO:5 wherein Xaa(29), Xaa(31) and Xaa(33) are individually any amino acid and Xaa(34) is Ala, Arg or Lys.
4. A DNA construct according to claim 3 wherein Xaa(29) and Xaa(31) are individually any amino acid except Lys, Arg or His.
5. A DNA construct according to claim 3 wherein Xaa(33) is Gly.
6. A DNA construct according to claim 3 wherein Xaa(34) is Arg or Lys.

7. A DNA construct according to claim 3 wherein Xaa(29) and Xaa(31) are individually Asp, Glu, Gln, Gly or Ala; Xaa(33) is Gly; and Xaa(34) is Arg.

8. A DNA construct according to claim 3 wherein Xaa(29) is Arg or Glu, Xaa(31) is Arg or Gln, Xaa(33) is Gly, and Xaa(34) is Arg, subject to the limitation that at least one of Xaa(29) and Xaa(31) is not Arg.

9. A DNA construct according to claim 1 wherein said TPO polypeptide consists of from 144 to 335 amino acid residues.

10. A DNA construct according to claim 1 wherein said TPO polypeptide consists of from 144 to 191 amino acid residues.

11. A DNA construct according to claim 1 wherein said TPO polypeptide consists of a sequence of amino acids selected from the group consisting of:

Ser(22) to Val(173) of SEQ ID NO:4;
Ser(22) to Arg(185) of SEQ ID NO:4;
Ser(22) to Asn(193) of SEQ ID NO:4;
Ser(22) to Phe(207) of SEQ ID NO:4; and
Ser(22) to Gln(235) of SEQ ID NO:4.

12. A DNA construct according to claim 1 wherein said TPO polypeptide is a human TPO polypeptide.

13. A DNA construct according to claim 1 further comprising a selectable marker.

14. A DNA construct comprising a first DNA segment encoding a polypeptide fusion consisting essentially of an amino-terminal secretory peptide as shown in SEQ ID

NO:5 wherein Xaa(29) is Arg or Glu, Xaa(31) is Arg or Gln, Xaa(33) is Gly, and Xaa(34) is Ala or Arg, joined to a TPO polypeptide of from 144 to 335 amino acids, wherein said first DNA segment is operably linked to one or more additional DNA segments that provide for its transcription.

15. A DNA construct according to claim 14 wherein said TPO polypeptide consists of from 144 to 191 amino acid residues.

16. A DNA construct according to claim 14 wherein said TPO polypeptide is a human TPO polypeptide.

17. A DNA construct according to claim 14 wherein said TPO polypeptide consists of a sequence of amino acids selected from the group consisting of:

Ser(22) to Val(173) of SEQ ID NO:4;
Ser(22) to Arg(185) of SEQ ID NO:4;
Ser(22) to Asn(193) of SEQ ID NO:4;
Ser(22) to Phe(207) of SEQ ID NO:4; and
Ser(22) to Gln(235) of SEQ ID NO:4.

18. A DNA construct according to claim 14 further comprising a selectable marker.

19. A cultured eukaryotic cell containing a DNA construct comprising:

a first DNA segment encoding a polypeptide fusion, said fusion comprising an amino-terminal secretory peptide joined to a TPO polypeptide, the fused sequences defining a proteolytic cleavage site at their junction; and

one or more additional DNA segments operably linked to said first DNA segment so as to provide for its transcription, wherein said secretory peptide is selected from the group consisting of:

native mammalian t-PA secretory peptides; and

mammalian t-PA secretory peptides modified to enhance proteolytic cleavage at said junction.

20. A yeast cell according to claim 19.

21. A yeast cell according to claim 20 wherein said cell is a *Saccharomyces cerevisiae* cell.

22. A yeast cell according to claim 20 wherein said cell is a *Pichia pastoris* cell.

23. A cultured mammalian cell according to claim 19.

24. A mammalian cell according to claim 23 which is a rodent cell.

25. A mammalian cell according to claim 23 which is a kidney cell.

26. A method for producing a thrombopoietin polypeptide comprising the steps of:

(a) culturing a eukaryotic cell containing a DNA construct comprising a first DNA segment encoding a polypeptide fusion, said fusion comprising an amino-terminal secretory peptide joined to a thrombopoietin (TPO) polypeptide, the joined peptide and polypeptide defining a proteolytic cleavage site at their junction; and one or more additional DNA segments operably linked to said first DNA segment so as to provide for its transcription, wherein said secretory peptide is selected from the group consisting of:

native mammalian tissue plasminogen activator (t-PA) secretory peptides; and

mammalian t-PA secretory peptides modified to enhance proteolytic cleavage at said junction,

wherein said cell expresses said first DNA segment
and said TPO polypeptide is secreted from the cell; and
(b) selectively recovering said TPO polypeptide.

INTERNATIONAL SEARCH REPORT

national Application No
PCT/US 95/14932

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/62 C07K14/52 C12N15/19 C12N1/19 C12N5/10
C12N15/58

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	NATURE, vol. 369, 16 June 1994 pages 565-568, S. LOK ET AL 'Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo' see the whole document ---	1,2, 9-13, 19-26
Y	FEBS LETTERS, vol. 353, 10 October 1994 pages 57-61, Y. SOHMA ET AL 'Molecular cloning and chromosomal localization of the human thrombopoietin gene' see the whole document ---	1,2, 9-13, 19-26
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* documents of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

9 April 1996

Date of mailing of the international search report

23.04.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Van der Schaal, C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/14932

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP,A,0 486 193 (LILLY CO ELI) 20 May 1992 see the whole document -----	1,2, 9-13, 19-26

International Application No
PCT/US 95/14932

Form PCT/ISA/210 (patent family annex) (July 1997)